Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2021–2026

OLIGOMED · Oligonucleotides for Medical Applications

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2021-01-01 → 2026-07-31
Финансиране от ЕС
4 138 063 €
Участници
15
Схема
MSCA-ITN

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Олигонуклеотидите се изследват като основа за нови лекарства и сензори при генетични заболявания, като например рак или болест на Хънтингтън. Разработването на такава платформа помага за създаването на по-ефективни методи за диагностика и лечение на наследствени мутации.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Oligonucleotides for Medical Applications

The project OLIGOMED will explore cutting edge chemistry, analysis, nano- and bio-technology of nucleic acids in a unique academy-clinics-industry environment. This will result in a reliable and flexible platform based on tailored nucleic acids systems that has the potential to become the next pillar of drug development. Over 4,000 human diseases are known to be monogenic (caused by a single genetic mutation) accounting for up to 40% of the work of hospital based paediatric practice. In the case of cancer, which is the most prominent genetic disease, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths by 2030. Therapies generally target the symptoms to aid quality of life. In certain cases, combination cancer therapy (radiation therapy, surgery, chemotherapy) can stabilise the disease and extend the life expectancy for early diagnosed patients, while the survival rate for patients with metastasis cancers still remains low. As for other inherited genetic diseases such as Huntington’s disease (HD), there is currently no cure. The overarching aims of OLIGOMED are: • To train 15 Early Stage Researchers (ESRs) through an interdisciplinary research and training network in order to produce highly skilled young scientists and future leaders for the rapidly growing field of ON therapeutics. • To unite world-class academic and industrial expertise in nucleic acid research, analysis, delivery and medical applications in order to develop the next generation ON therapeutics platform technologies. • Utilize the novel ON platform to develop innovative sensor tools, delivery systems and treatment options for genetic diseases with a great potential for licensing to Europe’s pharma industry.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The use of synthetic oligonucleotides (ONs, short DNA or RNA strands) in the treatment of genetic diseases is a rapidly growing field, and the most promising alternative to gene therapy or small molecules. Most pharmaceutical companies shift from in-house platform development to product-specific licensing and co-development to get ON based therapies past clinical trials. Therefore there is a growing and currently unmet need for a combined academic and industry-based multidisciplinary research to further advance the field by bringing together the separated and fragmented R&D efforts of diverse ON technologies.OLIGOMED will address these needs by:- uniting world-class academic and private sector expertise in ON chemistry, bio-analysis and medical applications- developing a next generation ON platform technology based on combining tailored synthetic ONs with smart delivery- optimising ON therapies through testing in medicinal environmentsWe will use these novel ON technologies to develop innovative treatment options for high-impact genetic diseases, i.e. Huntington’s disease, cardiovascular diseases and cancer.Our European intersectoral and multidisciplinary research and training network for 15 Early Stage Researchers (ESRs) will deliver:-highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine-top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing-transferable skills courses, specific industry relevant workshops and public engagement activitiesThis combination makes OLIGOMED a truly exciting programme for ESRs. The platform will immediately benefit to both European citizens and commercial partners. In the long term, OLIGOMED`s flexible platform technology will be taken forward by our private sector and research institutions for exploitation and will thus strengthen the European innovation capacity in the field of ON therapies.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз